📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. (2019)

First Author: Battisti NML

Attributed to: King's Health Partners Confidence in Concept funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s10549-019-05134-x

PubMed Identifier: 30656459

Publication URI: http://europepmc.org/abstract/MED/30656459

Type: Journal Article/Review

Volume: 174

Parent Publication: Breast cancer research and treatment

Issue: 3

ISSN: 0167-6806